Timm U, Zell M
Arzneimittelforschung. 1983;33(3):358-62.
A sensitive and specific HPLC-assay was developed for the determination of the benzodiazepine antagonist ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo-[1,5-a] [1,4]benzodiazepine-3-carboxylate (Ro 15-1788; envisaged INN: flumazepil) in plasma. Ro 15-1788 and the internal standard were extracted from plasma at a basic pH, separated from coextracted plasma components on a reversed-phase column and quantitated by means of a UV detector. Ro 15-1788 was extracted quantitatively from plasma in the concentration range 25.6 to 300 ng/ml. The sensitivity limit was about 10 ng/ml plasma using a 1-ml specimen. The method was shown to be specific with respect to several benzodiazepines and their main metabolites. The method was successfully applied to pharmacokinetic studies in man after oral and intravenous administration of Ro 15-1788.
开发了一种灵敏且特异的高效液相色谱法,用于测定血浆中的苯二氮䓬拮抗剂8-氟-5,6-二氢-5-甲基-6-氧代-4H-咪唑并[1,5-a][1,4]苯二氮䓬-3-羧酸乙酯(Ro 15-1788;设想的国际非专利药品名称:氟马西尼)。Ro 15-1788和内标在碱性pH下从血浆中萃取,在反相柱上与共萃取的血浆成分分离,并通过紫外检测器进行定量。在25.6至300 ng/ml的浓度范围内,Ro 15-1788可从血浆中定量萃取。使用1 ml样本时,灵敏度极限约为10 ng/ml血浆。该方法对几种苯二氮䓬及其主要代谢物具有特异性。该方法已成功应用于Ro 15-1788口服和静脉给药后人的药代动力学研究。